Adamas Pharmaceuticals

^{Priced, Nasdaq: ADMS}

Developing improved formulations of existing drugs for CNS disorders.

Industry: Health Care

First Day Return: -12.4%

ADMS

Developing improved formulations of existing drugs for CNS disorders.

IPO News for Adamas Pharmaceuticals

Diabetes/Alzheimer's biotech Vitae Pharmaceuticals sets terms for $60 million IPO 09/08/14
Diabetes/Alzheimer's biotech Vitae Pharmaceuticals files for a $55 million IPO 08/12/14
Seizure biotech Sage Therapeutics sets terms for $60 million IPO 07/08/14

IPO Data
IPO Date	04/09/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$48
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.adamaspharma.com
Headquarters	Emeryville, CA, United States
Founded	2000
Employees at IPO	22

IPO News for Adamas Pharmaceuticals

Adamas Pharmaceuticals (ADMS) Performance